BDTX
Black Diamond Therapeutics, Inc. · Healthcare
No insider bought or sold Black Diamond Therapeutics, Inc. in the last 12 months
BDTX over the last year
BDTX after insider buys
3 months after each buy, from the first price a copier could get.
8 buys since 2020 with 3 months of prices.
Every filing
73 insider filings since 2020, newest first
Versant Venture Capital Vi, L.P. · 10% owner
Ra Capital Management, L.P. · Director
Ali Behbahani · Director
Growth N Biotech V · 10% owner
Growth N Biotech V · 10% owner
David M. Epstein · Insider
Growth N Biotech V · 10% owner
Growth N Biotech V · 10% owner
Growth N Biotech V · 10% owner
Growth N Biotech V · 10% owner
Brent Hatzis-Schoch · Insider
Christopher D. Roberts · Chief Scientific Officer
Brent Hatzis-Schoch · Insider
Christopher D. Roberts · Chief Scientific Officer
Brent Hatzis-Schoch · Insider
Christopher D. Roberts · Chief Scientific Officer
Brent Hatzis-Schoch · Insider
Christopher D. Roberts · Chief Scientific Officer
Brent Hatzis-Schoch · Insider
Thomas Leggett · CFO
Christopher D. Roberts · Chief Scientific Officer
David M. Epstein · Insider
Brent Hatzis-Schoch · Insider
Thomas Leggett · CFO
Christopher D. Roberts · Chief Scientific Officer
David M. Epstein · Insider
Bradley J Phd Bolzon · Director and 10% owner
Versant Venture Capital Vi, L.P. · 10% owner
Versant Venture Capital Vi, L.P. · 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Versant Venture Capital Vi, L.P. · 10% owner
Versant Venture Capital Vi, L.P. · 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Versant Venture Capital Vi, L.P. · 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Christopher D. Roberts · Chief Scientific Officer
Brent Hatzis-Schoch · Insider
Versant Venture Capital Vi, L.P. · 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Thomas Leggett · CFO
Versant Venture Capital Vi, L.P. · 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Versant Venture Capital Vi, L.P. · 10% owner
Christopher D. Roberts · Chief Scientific Officer
David M. Epstein · Insider
Versant Venture Capital Vi, L.P. · 10% owner
Bradley J Phd Bolzon · Director and 10% owner
Bradley J Phd Bolzon · Director and 10% owner
About Black Diamond Therapeutics, Inc.
Black Diamond Therapeutics, Inc., a clinical-stage oncology company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is silevertinib, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in Phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as Phase 2 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in Phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Filings come from SEC EDGAR and prices from daily closes. Not investment advice.